FAKTOR-OPTIONSSCHEIN - BRISTOL-MYERS SQUIBB | Delayed Deutsche Boerse AG 09:26:35 04/06/2024 pm IST | ||
| 1.41 EUR | +2.17% |
|
| Current month | -14.81% | ||
| 1 month | +23.21% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 04/24/04 | 1.41 | +2.17% |
| 03/24/03 | 1.38 | -14.81% |
| 31/24/31 | 1.62 | -8.47% |
| 30/24/30 | 1.77 | +1.14% |
| 29/24/29 | 1.75 | +0.57% |
Delayed Quote Deutsche Boerse AG
Last update June 04, 2024 at 09:26 pm IST
More quotesStatic data
| Product type | Exotische Produkte |
|---|---|
| Buy / Sell | CALL |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | 
Société Générale
|
| WKN | SB0XYT |
| ISIN | DE000SB0XYT8 |
| Date issued | 08/06/2020 |
| Strike | 60.88 $ |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 8.88 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 16.54 € |
|---|---|
| Lowest since issue | 0.09 € |
| Spread | 0.01 € |
| Spread % | 0.70% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
41.77
USD
Average target price
53.19
USD
Spread / Average Target
+27.35%
- Stock Market
- Certificates
- Certificat
